[signal.]portfolio & asset diligence

Org: Demo Translational Institute — structured asset diligence, not investment advice.

← Portfolio

SOD1 Antisense Oligonucleotide

Edit / manage →

Amyotrophic lateral sclerosis

Phase 1/2Clinical entryAntisense oligonucleotideNeurodegenerationSupportive· medium conf3 evidence-linked claims2 snapshots

Overview

Disease area
Neurodegeneration
Indication
Amyotrophic lateral sclerosisMONDO:0004976
Mechanism of action
Allele-selective knockdown of mutant SOD1 transcript
Development stage
Phase 1/2
Institution
Lakeshore Neuroscience Institute
Principal investigators
R. Halvorsen, D. Whitfield
Targets
SOD1
Pathways
Proteostasis
Trial registry
—

Intake & funding

Applications
  • D. WhitfieldfundedUSD900,0002024-08-20
    Innovation award
Funding events
  • awardUSD900,000Innovation award2025-01-05

Timeline

state through time · newest first
  1. Q2 2025Series B raised
    Milestones
    • ·Dose escalation completed
    Accomplishments
    • ·Plasma NfL decline observed at high dose
    • ·Intrathecal delivery well tolerated
    Challenges
    • ·Small genetically defined population limits enrollment speed
    Next steps
    • ·Open registrational cohort
    • ·Align on accelerated approval package
    Risk themes:Enrollment of rare SOD1 genotype
  2. Q1 2025Grant + Series A blended
    Milestones
    • ·Phase 1/2 first cohort dosed
    Accomplishments
    • ·Target engagement confirmed via CSF SOD1 reduction
    Challenges
    • ·Neurofilament response heterogeneous across patients
    Next steps
    • ·Escalate dose
    • ·Pre-specify NfL responder analysis
    Risk themes:Surrogate-endpoint acceptance risk

Scientific assessment

1 claims
  • Target ValidationStrong

    Mutant SOD1 toxic gain-of-function is genetically validated; allele-selective knockdown is precedented by tofersen's neurofilament effect.

    datasetMONDO:0004976

Translational assessment

1 claims

Regulatory assessment

1 claims
  • Accelerated ApprovalModerate

    NfL as a surrogate endpoint has supported accelerated approval in SOD1-ALS, establishing a viable regulatory precedent.

    regulatoryaa-precedent

Commercial assessment

0 claims

No evidence linked yet.

Execution assessment

0 claims

No evidence linked yet.

Structured reviews

1 reviews
Supportive· medium confAcademicNeuromuscular panel2025-04-18
Strengths

Genetically validated target; NfL surrogate precedent.

Weaknesses

Heterogeneous biomarker response; small population.

Improvement areas

Pre-specify responder analysis and enrollment plan.

Internal rubric input (reviewer scoring — not a success probability)
Scientific validity
Translational readiness
Regulatory pathway
Commercial potential
Execution strength

Outcome

  • Clinical entry
    First-in-human Phase 1/2 dosing underway.2025-01-10

AI brief

flag off · defaultPhase 7

Runtime AI features are flag-gated and disabled by default. Set SIGNAL_LLM_ENABLED=1 (plus a provider key) to enable a grounded, source-cited brief generated from this asset's structured records — with forbidden-phrase and grounding validators enforcing no probability-of-success or buy/sell language.

Evidence tiers and reviewer rubric scores are internal, qualitative inputs — [signal.] surfaces never show a numeric probability of success or buy/sell language.